Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Products & Pipeline
    • OpRegen®
    • OPC1
    • VAC2
    • Renevia
  • Technologies
    • Cell Therapy
    • Other Technologies
      • Vision Restoration Programs
      • MS/Stroke Programs
      • HyStem® Delivery Technology
      • Renevia®
    • Patents & Trade Secrets
    • Scientific Publications
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu
  • Investors

    Lineage is a clinical-stage biotechnology company developing novel cell therapies

Investors

NYSE AMERICAN: LCTX

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 
VIEW STOCK QUOTE
Press Releases
December 28, 2020
Lineage Cell Therapeutics Provides End of Year Shareholder Letter
December 09, 2020
Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020
December 08, 2020
Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury
VIEW PRESS RELEASES
Events & Presentations
Lineage Cell Therapeutics at NobleCon17: Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
Jan 19, 2021 at 12:00 PM EST
Lineage Cell Therapeutics at FORCE Wealth Webinar: The Eyes of the World
Jan 14, 2021 at 12:00 PM EST
Lineage Cell Therapeutics at H.C. Wainwright & Co. Inc. 2021 Virtual BioConnect Conference
Jan 4, 2021
VIEW EVENTS & PRESENTATIONS
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top